Abstract:Purpose: MicroRNAs (miRNAs) are a major class of small endogenous RNA molecules that posttranscriptionally regulate the expression of most genes in the human genome. miRNAs are often located in chromosomal fragile sites, which are suscept-ible to amplification or deletion. Chromosomal deletions are frequent events in breast cancer cells. Deletion and loss of heterozygosity at 17p13.3 have been reported in 49% of breast cancers. The aim of the current study was to evaluate potential expression alterations of miR-22, miR-132, and miR-212, which are located on the 17p13.3 locus and are required for mammary gland development. Methods: A matched case-control study was conducted, which included 36 pairs of tumor and matched nontumor surgical specimens from patients diagnosed with breast invasive ductal carcinoma. Formalin-fixed paraffin-embedded samples from archival collections at the pathology department of Shariati Hospital were prepared for RNA extraction using the xylene-ethanol method before total RNA was isolated with TRIzol Reagent. Specific primers were designed for cDNA synthesis and miRNA amplification. The expression of miRNAs was then evaluated by real-time polymerase chain reaction (RT-PCR). Results: According to our RT-PCR data, the miR-212/miR-132 family was downregulated in breast cancer (0.328-fold, p<0.001), and this reduced expression was the most prominent in high-grade tumors. In contrast, miR-22 exhibited a significant upregulation in breast tumor samples (2.183-fold, p=0.040). Conclusion: Consistent with the frequent deletion of the 17p13.3 locus in breast tumor cells, our gene expression data demonstrated a significant downregulation of miR-212 and miR-132 in breast cancer tissues. In contrast, we observed a significant upregulation of miR-22 in breast tumor samples. The latter conflicting result may have been due to the upregulation of miR-22 in stromal/cancer-associated fibroblasts, rather than in the tumor cells.

MicroRNA-222 Expression as a Predictive Marker for Tumor Progression in Hormone Receptor-Positive Breast Cancer

Prognostic Value of miR-222 in Various Cancers: a Systematic Review and Meta-Analysis.

High Expression of Microrna-223 Indicates a Good Prognosis in Triple-Negative Breast Cancer.

Down-Regulation of miR-194-5p for Predicting Metastasis in Breast Cancer Cells

Elevated expression of tumor miR-222 in pancreatic cancer is associated with Ki67 and poor prognosis

Mir-221/222 Promote Cancer Stem-Like Cell Properties and Tumor Growth of Breast Cancer Via Targeting PTEN and Sustained Akt/NF-κB/COX-2 Activation.

Increased Expression of Mir-222 is Associated with Poor Prognosis in Bladder Cancer

Tumor-promoting Properties of Mir-8084 in Breast Cancer Through Enhancing Proliferation, Suppressing Apoptosis and Inducing Epithelial–mesenchymal Transition

MicroRNA-520g Promotes Epithelial Ovarian Cancer Progression and Chemoresistance Via DAPK2 Repression

Serum miR-222-3p as a Double-Edged Sword in Predicting Efficacy and Trastuzumab-Induced Cardiotoxicity for HER2-Positive Breast Cancer Patients Receiving Neoadjuvant Target Therapy

Expression of miR-221 and miR-18a in patients with hepatocellular carcinoma and its clinical significance

An Estrogen Receptor Α Suppressor, Microrna‐22, is Downregulated in Estrogen Receptor Α‐positive Human Breast Cancer Cell Lines and Clinical Samples

miR-221/222 promote cancer stem-like cell properties and tumor growth of breast cancer via targeting PTEN and sustained Akt/NF-κB/COX-2 activation

The role of miR-223 in breast cancer; an integrated analysis

Mir-221/222 Promotes S-phase Entry and Cellular Migration in Control of Basal-Like Breast Cancer.

Aberrant Expression of Breast Development-Related MicroRNAs, miR-22, miR-132, and miR-212, in Breast Tumor Tissues

Correlation of Mir-155 on Formalin-Fixed Paraffin Embedded Tissues with Invasiveness and Prognosis of Breast Cancer

Role of miR-221/222 in Tumor Development and the Underlying Mechanism.

Advances of miR-221/222 in tumors

Potential Diagnostic and Prognostic Utility of miR-141, miR-181b1, and miR-23b in Breast Cancer

Expression profile and functional analysis of miR-301b in patients with breast cancer: A bioinformatics, biochemical, and histopathological study